Welcome to our dedicated page for Organigram Global news (Ticker: OGI), a resource for investors and traders seeking the latest updates and insights on Organigram Global stock.
News about Organigram Global Inc. (NASDAQ: OGI, TSX: OGI) focuses on its activities as a Canadian cannabis cultivator, manufacturer and brand owner operating under the Cannabis Act and Cannabis Regulations. Company announcements highlight its position as Canada’s number one cannabis company by market share in the recreational segment, as well as developments across cultivation, product innovation, beverages and international expansion.
Investors and observers following OGI news will see regular updates on quarterly and annual financial results, including net revenue trends, adjusted gross margin, adjusted EBITDA and free cash flow, as reported in its earnings releases. These updates often discuss the impact of acquisitions such as Motif Labs Ltd. and Collective Project Limited on revenue growth, extraction capabilities and beverage market participation, along with commentary on cost efficiencies and synergy realization.
Organigram’s news flow also covers product and brand launches. Examples include new SHRED gummies formats, Big Bag O’ Buds strains, BOXHOT infused pre-rolls, Trailblazer blunts, Rizzlers vapes and the happly hemp-derived THC brand in the United States. The company highlights its use of FAST™ nanoemulsion technology in ingestible products and describes how these offerings are designed around consumer preferences, including mood-based formulations.
Another important theme in Organigram news is international and policy-related activity. Releases describe record international sales, progress toward EU-GMP certification for the Moncton facility, exclusive genetics agreements with Phylos Bioscience Inc., and polling and economic reports that position legal cannabis as a contributor to Canada’s GDP, jobs and innovation. Corporate governance and leadership updates, such as CEO succession plans and executive appointments, are also communicated through news releases. For a fuller picture of OGI’s evolving strategy and operations, readers can review this ongoing stream of company disclosures.
Organigram (NASDAQ: OGI) will report second quarter fiscal 2026 results for the period ended March 31, 2026 on Tuesday, May 12, 2026, before market open.
The company will host a conference call on the same day at 8:00 am ET; registration and live webcast links are provided, and a replay will be posted within 24 hours and archived for 90 days.
Organigram (NASDAQ: OGI) closed its acquisition of Sanity Group for an upfront €107.3 million purchase price (paid as €78.0 million cash and €29.3 million in shares) pursuant to a Feb 18, 2026 share purchase agreement.
The company also closed a €40.3 million private placement/b) with BAT and secured senior secured credit facilities of up to . Max Konrad Narr was appointed to the board for the Earnout Period, and the transaction fully deployed Organigram’s Jupiter strategic investment pool.
Organigram (NASDAQ: OGI) announced that shareholders approved the acquisition of Sanity Group GmbH and a related private placement with BT DE Investments (British American Tobacco) at the March 30, 2026 annual meeting by 93% of votes cast. The Transaction includes issuance of up to 96,287,602 common shares and is expected to close in April 2026 subject to customary conditions, completion of the Private Placement and ATB Financial senior secured credit facilities. Sanity generated positive EBITDA in 2025. The deal is described as financially accretive, creating a vertically integrated European hub and expanding Organigram into the German medical cannabis market.
Organigram (NASDAQ: OGI, TSX: OGI) has mailed a management information circular for an annual and special meeting on March 30, 2026 to approve its proposed acquisition of Sanity Group GmbH.
Consideration includes an upfront €113.4 million (€80.0M cash + €33.4M in Organigram shares at $3.00 each) and an earnout of up to €113.8 million. A BAT private placement of C$65.2M is planned to fund the cash portion. Closing requires TSX approval, NASDAQ notification and German FDI clearance.
Organigram (NASDAQ: OGI) launched SHRED Shotz, a 65ml single‑serve cannabis beverage powered by its FAST™ nanoemulsion platform designed for a 15‑minute onset.
The move extends the SHRED brand—which surpassed $200 million in retail sales in 2025—into a compact format targeting taste, convenience and broader beverage occasions.
Organigram (NASDAQ:OGI) is launching Edison and BOXHOT medical vape and pastille products in Australia, introducing 10 SKUs and shipping single‑strain live terpenes from Canada. The products will distribute via Leafio, expected to reach >4,000 pharmacies, and will debut at the United in Compassion symposium Feb 26–28.
The move expands Organigram’s non‑flower portfolio into a growing Australian medical cannabis market and highlights ready‑to‑consume formats and science‑led formulations.
Organigram (NASDAQ:OGI / TSX:OGI) announced a C$65.2 million private placement with BAT (NYSE:BTI) to help fund its acquisition of Sanity Group. BAT will subscribe for 14,027,074 shares at C$3.00 and exercise top-up rights for 9,897,356 shares at C$2.335854.
Proceeds, plus restricted cash and up to $60 million credit facilities, will fund the cash portion of the acquisition and working capital. Issuances may include non-voting preferred shares to keep BAT below a 30% voting threshold; conversion mechanics cap beneficial ownership at 49%.
Organigram (NASDAQ: OGI) agreed to acquire Berlin-based Sanity Group for upfront consideration of €113.4 million and a maximum earnout of €113.8 million, funded by cash, a credit facility and an expected C$65.2 million equity investment by BAT. Sanity reported net revenue growth from €9M (2023) to €60M (2025) and positive 2025 EBITDA.
The transaction is subject to shareholder, TSX and German foreign investment approvals and is expected to close in Q2 2026, conditional on financing and customary closing conditions.
Organigram (NASDAQ: OGI) reported Q1 Fiscal 2026 results for the quarter ended December 31, 2025, showing strong year-over-year growth. Gross revenue was $97.3M (+46% YoY) and net revenue $63.5M (+49% YoY). Adjusted EBITDA rose to $5.3M (+273% YoY). Cash and short-term investments totaled $63.0M.
Key operational highlights include a 43% increase in kilograms harvested, expanded U.S. retail footprint to 11 states, and a powdery mildew genetic screening breakthrough to improve yield stability.
Organigram (NASDAQ: OGI) will report first quarter fiscal 2026 results for the period ended December 31, 2025 on Tuesday, February 10, 2026, before market open. A conference call and live webcast are scheduled for 8:00 am Eastern Time to discuss results.
Registration is required for the call; a replay will be available within 24 hours and archived for 90 days at the company investor site.